

Phase I trial: MM-120-101

Submission date 14/05/2024	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 21/05/2024	Overall study status Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 20/05/2024	Condition category Other	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Public, Scientific, Principal Investigator

Contact name

Dr David Gregory

Contact details

11 Tiger Court, Kings Drive Prescott
Liverpool
United Kingdom
L34 1BH
+44 (0)151 4824700
davidgregory@macplc.com

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

1007602

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

IRAS 1007602

Study information

Scientific Title

Phase I trial: MM-120-101

Study objectives

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 18/09/2023, Wales Research Ethics Committee 1 Cardiff (Health and Care Research Wales, Castlebridge 4, 15-19 Cowbridge Road, East Cardiff, CF11 9AB, United Kingdom; 02922940912; wales.rec1@wales.nhs.uk), ref: 23/WA/0112

Study design

Phase 1 study in 30 healthy volunteers

Primary study design

Not Specified

Secondary study design

Study setting(s)

Pharmaceutical testing facility

Study type(s)

Other, Safety

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Healthy volunteers

Interventions

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Drug

Pharmaceutical study type(s)

Pharmacokinetic

Phase

Phase I

Drug/device/biological/vaccine name(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome measure

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Secondary outcome measures

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Overall study start date

18/04/2023

Completion date

19/12/2023

Eligibility**Key inclusion criteria**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)

Healthy volunteer

Age group

Adult

Sex

Both

Target number of participants

30

Key exclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

13/10/2023

Date of final enrolment

04/12/2023

Locations

Countries of recruitment

England

United Kingdom

Study participating centre**MAC Clinical Research Liverpool**

11 Tiger Court
King's Business Park
Liverpool
United Kingdom
L34 1BH

Study participating centre**MAC Clinical Research Manchester**

Citylabs 1.0
Nelson St
Manchester
United Kingdom
M13 9NQ

Sponsor information

Organisation

Mind Medicine Inc

Sponsor details

One World Trade Centre, Suite 8500
New York
United States of America
NY 10007
+1 513 476 9666
aengel@mindmed.co

Sponsor type

Research organisation

Website

Funder(s)

Funder type

Research organisation

Funder Name

Mind Medicine Inc

Results and Publications

Publication and dissemination plan

Full trial details will be published up to 30 months after the end of the trial. Publication of some trial details is deferred because of the high commercial sensitivity of this phase I study. Results will be posted on or after the date of publication of full trial details.

Intention to publish date

19/06/2026

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available due to commercial sensitivity of the data

IPD sharing plan summary

Not expected to be made available